A PYMNTS Company

From Astra-Zeneca to Pfizer: When Protection of Originators Patents Ceases to be a Right and Becomes an Abuse of Dominance

BY | July 27, 2012

Stefano Grassani, Jul 27, 2012 On Jan. 11, 2012, the Italian Antitrust Authority (“IAA”) found Pfizer Inc. and its Swedish and Italian subsidiaries guilty of abuse of dominant position pursuant…

Stefano Grassani, Jul 27, 2012

On Jan. 11, 2012, the Italian Antitrust Authority (“IAA”) found Pfizer Inc. and its Swedish and Italian subsidiaries guilty of abuse of dominant position pursuant to Article 102 of the Treaty on the Functioning of the European Union. The IAA alleged that these subsidiaries jointly engaged in unlawful exclusionary conducts so as to unlawfully extend IP exclusive rights over Pfizer’s Xalatan blockbuster drug, deterring or, in any event, delaying e

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.215.16.238

Please verify email or join us to access premium content!